{"filings":[{"id":760117,"accession_number":"0001193125-26-249951","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-06-01T12:51:21+00:00","items":["1.01","9.01"],"status":"ready","headline":"Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.","Edgewise to focus on cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003).","Upfront proceeds fully fund EDG-7500 development through potential approval.","On track to report 12-week CIRRUS-HCM Part D data in Q2 2026.","Transaction expected to close Q3 2026, subject to HSR and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94885,"accession_number":"0001104659-26-056783","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.","R&D expense $42.7M (up 16% YoY) driven by EDG-7500 and EDG-15400 clinical activity, partly offset by lower sevasemten costs.","Long-term MESA OLE data shows sevasemten stabilizes function in Becker up to 3.5 years; 99% enrollment from prior trials.","Pivotal GRAND CANYON sevasemten top-line results expected Q4 2026; marketing application planned H1 2027.","CIRRUS-HCM Part D (EDG-7500) 12-week data in HCM expected Q2 2026; Phase 3 initiation H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107579,"accession_number":"0001104659-26-020108","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.","Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.","GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.","CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.","EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123938,"accession_number":"0001104659-25-114660","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Christopher Martin to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.","Appointment effective November 19, 2025; term expires at 2028 annual meeting.","Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).","Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123937,"accession_number":"0001104659-25-109295","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.","Nofi's annual base salary: $465,000, target cash bonus 40% of salary, plus stock option for 262,500 shares and 43,750 RSUs.","Carruthers to remain employee until Jan 31, 2026, then consultant through Oct 31, 2026, with continued equity vesting.","Nofi previously Chief Accounting Officer at SpringWorks Therapeutics; brings 30+ years life sciences finance experience.","No disagreement between Carruthers and company; transition supports Edgewise's late-stage clinical and commercialization prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123936,"accession_number":"0001104659-25-107419","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.","R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.","Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.","GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.","EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140600,"accession_number":"0001104659-25-074987","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.","MESA trial data: 99% enrollment; NSAA scores stable over 18 months in Becker participants.","Phase 2 LYNX/FOX trials in Duchenne identify 10 mg sevasemten dose for Phase 3; FDA meeting planned Q4 2025.","CIRRUS-HCM (EDG-7500) trial advancing; Part D enrolling; update expected Q4 2025.","GRAND CANYON pivotal trial in Becker fully enrolled; topline data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158313,"accession_number":"0001104659-25-063028","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.","FDA Type C: NSAA endorsed for traditional approval; CANYON alone insufficient; GRAND CANYON may serve as single pivotal study.","GRAND CANYON on track for topline data Q4 2026; highly powered to show NSAA difference vs placebo over 18 months.","Duchenne Phase 2 LYNX/FOX: 10 mg dose selected for Phase 3; well-tolerated; FOX suggests slower decline in post-gene therapy patients.","Plans to meet FDA Q4 2025 for Phase 3 Duchenne design; pivotal study initiation expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158312,"accession_number":"0001104659-25-045896","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.","Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.","Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.","Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158311,"accession_number":"0001104659-25-030870","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics prices $200M common stock offering at $20.13 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.","Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).","Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.","Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.","Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158310,"accession_number":"0001104659-25-030839","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.","NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.","No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.","Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176688,"accession_number":"0001104659-25-019498","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.","Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.","Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.","On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176687,"accession_number":"0001104659-25-005075","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edgewise Therapeutics promotes Behrad Derakhshan to COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Behrad Derakhshan, Ph.D., appointed Chief Operating Officer effective January 8, 2025.","Previously served as Chief Business Officer since September 2020.","Annual base salary increased from $478,400 to $520,000; target bonus raised to 45%.","No family relationships with any director or executive officer of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193526,"accession_number":"0001104659-24-129001","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise Phase 2 CANYON trial meets primary endpoint; sevasemten reduces CK by 28% in Becker muscular dystrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: CK decreased 28% vs placebo over months 6-12 in adults (p=0.02).","Key secondary NSAA showed 1.1-point trend favoring sevasemten (p=0.16); treatment group had more advanced disease at baseline.","TNNI2 biomarker reduced 77% vs placebo (p<0.001); functional tests (10-m walk, stair climb, 100-m) trended positive.","Sevasemten well-tolerated; no new safety concerns in adults or adolescents.","GRAND CANYON pivotal cohort enrollment on track for Q1 2025; 99% of eligible patients entered open-label extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193525,"accession_number":"0001104659-24-115077","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.","R&D expenses $32.2M (up $1.5M QoQ); G&A $8.2M (up $0.8M QoQ).","Top-line CANYON (Becker) data expected December 2024; EDG-7500 28-day data Q1 2025.","CIRRUS-HCM single dose: 67% mean reduction in resting LVOT gradient; no meaningful LVEF change.","LYNX (Duchenne) data due Q4 2024; FOX trial over-enrolled within two months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209832,"accession_number":"0001104659-24-088426","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics adopts 2024 Inducement Plan, reserving 2M shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted 2024 Inducement Equity Incentive Plan effective August 10, 2024, reserving 2,000,000 shares of common stock.","Plan allows grants of nonstatutory stock options, SARs, restricted stock, RSUs, and performance awards as hiring inducements.","Adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) – limited to new employees or merger hires.","Terms are substantially similar to the 2021 Equity Incentive Plan; no Exchange Program is permitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209831,"accession_number":"0001104659-24-087031","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.","Cash and marketable securities $511.8M as of June 30, 2024.","Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.","Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.","LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228033,"accession_number":"0001104659-24-070114","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Edgewise shareholders elect directors, ratify KPMG, approve officer exculpation charter amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Thompson, Koch, and Fox with 65M–75M shares For vs 6.9M–17.3M Against; broker non-votes 8.2M.","Ratified KPMG LLP as independent auditor for FY 2024: 90.5M For, 4K Against, 35K Abstain.","Approved certificate amendment to limit officer liability per Delaware law: 81.4M For, 938K Against, 1.4K Abstain; broker non-votes 8.2M.","Amendment to Article IX of the certificate of incorporation was filed on June 10, 2024, effective upon filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228032,"accession_number":"0001104659-24-059674","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.","Prior $125M ATM program with BofA Securities terminated on May 10, 2024.","Leerink will receive up to 3% commission on gross proceeds from shares sold.","Company has no obligation to sell shares and may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228031,"accession_number":"0001104659-24-059136","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.","Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.","Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.","GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.","EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228030,"accession_number":"0001104659-24-057783","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Morris replaces Peter Thompson on the Audit and Compensation Committees.","She brings 30+ years of biotech leadership, including CEO roles at Syndax and Affymax.","Annual cash retainer of $40,000 plus $7,500 for Audit and $5,000 for Compensation Committee service.","New director stock option grant with ~$500,000 fair value, vesting monthly over 3 years.","Appointment fills vacancy left by Kenneth Harrison's resignation in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}